Sign in

Govt may allow private labs to conduct genome sequencing

The government may allow private laboratories to conduct whole genome sequencing of Sars-Cov-2 positive samples to scale up testing facilities in the wake of the threat posed by the heavily mutated Omicron variant.

Updated on: Dec 14, 2021, 02:01:13 IST
By , Hindustan Times, New Delhi
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

The government may allow private laboratories to conduct whole genome sequencing of Sars-Cov-2 positive samples to scale up testing facilities in the wake of the threat posed by the heavily mutated Omicron variant, people familiar with the development said.

Samples being examined at the Genome Sequencing Lab and RT-PCR laboratory at Directorate of Medical and Rural Health Services campus amid fear of the Omicron variant, in Chennai on November 29. (ANI)
Samples being examined at the Genome Sequencing Lab and RT-PCR laboratory at Directorate of Medical and Rural Health Services campus amid fear of the Omicron variant, in Chennai on November 29. (ANI)

“There have been talks around it, but no final decision has been made yet on the issue,” a central government official said on condition of anonymity.

There was mention of this in Parliament discussions in the ongoing winter session.

“There are 36 laboratories for genome sequencing in the country currently. These laboratories can do whole genome sequencing of up to 30,000 positive samples, and the capacity is being increased with the help of private laboratories,” health minister Mansukh Mandaviya said last week while speaking on the Omicron variant during question hour on Friday.

It would make sense to include private labs if the Centre intends to scale up genetic sequencing to detect mutations early, industry insiders said.

“India is performing probably the lowest amount of genetic testing anywhere in the world. We are probably not doing (genome sequencing) of even 1% of the positive samples, whereas there are countries like Israel that are performing genome sequencing of all positive samples. Even the US is doing it for 20-30% of its positive samples. The next thing is to expand our genetic testing like we did for molecular testing,” said GSK Velu, chairman and managing director of Neuberg Diagnostics, one of the country’s largest diagnostic laboratories.

  • Rhythma Kaul
    ABOUT THE AUTHOR
    Rhythma Kaul

    Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More